Assessment of bleeding risk in cancer patients treated with anticoagulants for venous thromboembolic events

INTRODUCTION: Anticoagulant is the cornerstone of the management of VTE at the cost of a non-negligible risk of bleeding. Reliable and validated clinical tools to predict thromboembolic and hemorrhagic events are crucial for individualized decision-making for the type and duration of anticoagulant t...

Descripción completa

Detalles Bibliográficos
Autores principales: Poénou, Géraldine, Tolédano, Emmanuel, Helfer, Hélène, Plaisance, Ludovic, Happe, Florent, Versini, Edouard, Diab, Nevine, Djennaoui, Sadji, Mahé, Isabelle
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Cardiovascular Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475592/
https://www.ncbi.nlm.nih.gov/pubmed/37671139
http://dx.doi.org/10.3389/fcvm.2023.1132156

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10475592/
https://www.ncbi.nlm.nih.gov/pubmed/37671139
http://dx.doi.org/10.3389/fcvm.2023.1132156

Ejemplares similares